Launay-Vacher Vincent, Spano Jean-Philippe, Janus Nicolas, Gligorov Joseph, Ray-Coquard Isabelle, Oudard Stéphane, Pourrat Xavier, Morere Jean-François, Beuzeboc Philippe, Deray Gilbert
Department of Nephrology, Hôpital Pitié-Salpêtrière, Paris, France.
Crit Rev Oncol Hematol. 2009 May;70(2):124-33. doi: 10.1016/j.critrevonc.2008.09.012. Epub 2008 Nov 5.
The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study which demonstrated the high prevalence of abnormal renal function in a population of 4684 solid tumor patients. Among them, 50-60% had decreased renal function, and 80% were treated with anticancer drugs that either necessitated dosage adjustment in case of renal insufficiency (RI) or were potentially nephrotoxic drugs. Since elderly patients are well-known to have reduced renal function, either due to physiological aging or their disease/medication history, a subgroup analysis of this particular population of patients was performed. In 1553 IRMA patients whose age was > or =65 years, the prevalence of RI was very high in spite of normal serum creatinine values in most cases. Anticancer drugs used may be nephrotoxic or need dosage adjustment in a high number of cases.
肾功能不全与抗癌药物（IRMA）研究是一项法国全国性的观察性研究，该研究表明在4684例实体瘤患者群体中肾功能异常的患病率很高。其中，50%至60%的患者肾功能下降，80%的患者接受了抗癌药物治疗，这些药物在肾功能不全（RI）时需要调整剂量，或者是潜在的肾毒性药物。由于众所周知老年患者肾功能会下降，这要么是由于生理衰老，要么是由于他们的疾病/用药史，因此对这一特定患者群体进行了亚组分析。在1553例年龄≥65岁的IRMA患者中，尽管大多数病例血清肌酐值正常，但RI的患病率仍然很高。所使用的抗癌药物在很多情况下可能具有肾毒性或需要调整剂量。
